Home » Stocks » WVE

Wave Life Sciences Ltd. (WVE)

Stock Price: $9.10 USD -0.09 (-0.98%)
Updated December 3, 4:00 PM EST - Market closed

WVE Stock Price Chart

Key Info

Market Cap 443.88M
Revenue (ttm) 13.04M
Net Income (ttm) -177.89M
Shares Out 38.36M
EPS (ttm) -5.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $9.10
Previous Close $9.19
Change ($) -0.09
Change (%) -0.98%
Day's Open 9.27
Day's Range 9.00 - 9.50
Day's Volume 331,506
52-Week Range 6.94 - 37.60

WVE Stock News

Seeking Alpha - 3 weeks ago

Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 weeks ago

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -17.81% and -76.49%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for t...

GlobeNewsWire - 3 weeks ago

Results from all cohorts of PRECISION-HD1 and PRECISION-HD2 clinical trials and initial OLE data on track for 1Q 2021

Zacks Investment Research - 1 month ago

Wave Life Sciences (WVE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for peopl...

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for pe...

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for pe...

The Motley Fool - 2 months ago

Investors liked an analyst's upgrade of the biotech stock.

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for pe...

Zacks Investment Research - 2 months ago

The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.

Other stocks mentioned: BBC, BTEC, IBBJ, IDNA, MRNS, NVUS, PTH, SAVA
Zacks Investment Research - 2 months ago

Investors need to pay close attention to Wave Life Sciences (WVE) stock based on the movements in the options market lately.

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for pe...

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for pe...

Seeking Alpha - 3 months ago

Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -11.65% and -57.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the st...

Benzinga - 3 months ago

Shares of WAVE Life Sciences (NASDAQ:WVE) moved higher by 1% in pre-market trading after the company reported Q2 results.

GlobeNewsWire - 3 months ago

Data from 32 mg cohorts of both PRECISION-HD trials and PRECISION-HD OLE trials expected in 1Q 2021

GlobeNewsWire - 3 months ago

Neurology pipeline discussion will include new preclinical data for C9orf72 program for ALS and FTD

Zacks Investment Research - 4 months ago

Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for peo...

Zacks Investment Research - 4 months ago

Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 5 months ago

Investors need to pay close attention to Wave Life Sciences (WVE) stock based on the movements in the options market lately.

GlobeNewsWire - 6 months ago

Newly created position will focus on translating advancements from PRISM platform into new therapeutic candidates Newly created position will focus on translating advancements from PRISM platf...

Seeking Alpha - 6 months ago

Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -2.99% and -42.72%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the st...

Benzinga - 6 months ago

Shares of WAVE Life Sciences (NASDAQ:WVE) were unchanged at $7.97 after the company reported Q1 results.

GlobeNewsWire - 6 months ago

Data from both PRECISION-HD clinical trials expected in 2H 2020

Seeking Alpha - 9 months ago

Wave Life Sciences Ltd. (WVE) CEO Dr.

Zacks Investment Research - 9 months ago

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -11.49% and -57.39%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for th...

Zacks Investment Research - 9 months ago

Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 10 months ago

Wave Life Sciences Ltd. (WVE) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

InvestorPlace - 11 months ago

Wave Life Sciences (WVE) news for Monday has WVE stock taking a beating on early data from its Huntington’s disease trial. The post Wave Life Sciences News: WVE Stock Crashes 50% on Huntington...

24/7 Wall Street - 11 months ago

Wave Life Sciences Ltd. (NASDAQ: WVE) shares dropped sharply to start out the week after the company announced topline data from its ongoing midstage trial in Huntington’s disease.

Investors Business Daily - 11 months ago

Wave Life Sciences stock collapsed Monday after the biotech company's experimental Huntington's disease treatment underperformed a rival drug from Roche and Ionis Pharmaceuticals. The post Wh...

Seeking Alpha - 11 months ago

Wipeout In Wave Life Sciences

GlobeNewsWire - 11 months ago

WVE-120102 demonstrates statistically significant reduction in disease-causing mutant HTT protein in CSF vs. placebo

Zacks Investment Research - 11 months ago

Investors need to pay close attention to Wave Life Sciences (WVE) stock based on the movements in the options market lately.

InvestorPlace - 11 months ago

Wave Life Sciences (WVE) news for Monday about it giving up on a Duchenne muscular dystrophy drug is hitting WVE stock hard. The post Wave Life Sciences News: WVE Stock Slammed 54% by Duchenne...

The Motley Fool - 11 months ago

A lack of efficacy in a lead drug candidate is not what investors were expecting.

GlobeNewsWire - 11 months ago

No change from baseline in dystrophin observed in Phase 1 open-label extension study

Seeking Alpha - 11 months ago

Wave Life Sciences' Suvodirsen May Be Much Better Than Sarepta's Commercialized Eteplirsen, But May Fall Short Of Sarepta's Newer Generation SRP-5051

Zacks Investment Research - 1 year ago

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -6.47% and -53.54%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for th...

GlobeNewsWire - 1 year ago

Suvodirsen is an investigational stereopure oligonucleotide in development for the treatment of DMD patients amenable to exon 51 skipping

GlobeNewsWire - 1 year ago

Wave leadership to present updates on multiple preclinical programs and discuss advances in PRISM™ platform Wave leadership to present updates on multiple preclinical programs and discuss adva...

GlobeNewsWire - 1 year ago

New independent directors bring deep expertise in drug development, commercial operations and government affairs New independent directors bring deep expertise in drug development, commercial ...

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for peo...

Zacks Investment Research - 1 year ago

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -16.19% and -51.61%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the st...

Zacks Investment Research - 1 year ago

Sarepta's (SRPT) shares surge after safety issues are observed in Pfizer's early-stage clinical study related to its gene therapy for DMD.

Other stocks mentioned: SRPT
Zacks Investment Research - 1 year ago

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -14.29% and -68.69%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the s...

Zacks Investment Research - 1 year ago

Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

About WVE

Wave Life Sciences, a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It focuses on programs in neurology in the central nervous system and neuromuscular system. The company has a re... [Read more...]

Industry
Biotechnology
IPO Date
Nov 11, 2015
CEO
Paul Bolno
Employees
301
Stock Exchange
NASDAQ
Ticker Symbol
WVE
Full Company Profile

Financial Performance

In 2019, WVE's revenue was $15.98 million, an increase of 10.89% compared to the previous year's $14.41 million. Losses were -$193.64 million, 32.0% more than in 2018.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for WVE stock is "Buy." The 12-month stock price forecast is 16.57, which is an increase of 82.09% from the latest price.

Price Target
$16.57
(82.09% upside)
Analyst Consensus: Buy